Our findings suggest [18F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to uniquely compete with [18F]MK-6240 binding in DSAD and provide preliminary insights to the off-target nonspecific binding of [18F]MK-6240 in postmortem meninges. This evidence concerns the gene MAPT and Alzheimer disease.